[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adult-all\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adult-all":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,72,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100572029","virtual-reality-infused-treadmill-training-on-aging-related-outcomes-100572029",false,"NCT06727942","Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes","Toward Healthy Living: Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes","V-TARGET","Inclusion Criteria:\n\n1. adults aged up to 75 years old\n2. able to walk independently, without use of an assistive device\n3. English speaking\n\nExclusion Criteria:\n\n1. self-disclosed limited mobility in joint(s) due to arthritis or other condition that would prevent participation\n2. any ongoing orthopedic injury\n3. cardiac surgery or any ongoing cardiovascular issues preventing participation or physical activity.\n4. motor\u002Fcognitive disorders (Alzheimer's disease, Parkinson's disease, dementia, etc.)\n5. use of a wheelchair",true,"ALL","18 Years","75 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","Age-associated motor and cognitive deficits increase the risk of falls, a major cause of morbidity and mortality. Emerging evidence suggests that inflammatory mediators lead to impaired functional capacity and frailty in the elderly and suggests that immune system mediated inflammation in the brain play an important role in cognitive decline. Substantial literature has also demonstrated that age-targeted physical activity training are promising strategies for promoting the motor-cognitive process across the adult lifespan. Recently, the virtual reality (VR) application has been implemented in the neuropsychological rehabilitation settings suggesting that the VR-infused daily living activities may benefit the transfer of intervention outcomes and to promote autonomy in function of daily living such as cooking or grocery shopping. However, it remains unclear the effect of the VR-based exercise intervention (motor-cognitive impact) on older adults' cognitive function and fall prevention. The literature suggests that the similarity of VR exercises with real life activities may improve generalizability by extending the transfer of gains of training to everyday living and promote some aspects of quality of life in older adults. It is also unclear to what extent these aging-associated motor- cognitive changes may be affected by VR rehab games and whether systemic- and neuro-inflammation is ameliorated by this novel intervention in older adults.\n\nThis purpose of this study is to design and implement a Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes (V-TARGET) intervention, focusing on adults (aged up to 75 years old). The study will compare the effects of V-TARGET intervention (self-paced treadmill-simulator exercise with VR rehab games) against a control group on motor-cognitive function, health-related quality of life (HRQOL), circulating inflammatory markers and cerebral\u002Fperipheral blood flow through this 5-week intervention (2 times\u002Fweek, 30-minutes\u002Fsession, 10 sessions total).",[29],"Adult ALL",[31,32,33,34],"Virtual-Reality","Fall Risk Invention","Physical Activity","Neuromotor Rehabilitation","RECRUITING","2026-05-26",{"date":38,"type":39},"2026-05-29","ACTUAL",{"date":41,"type":39},"2022-05-10",{"date":43,"type":23},"2027-08-31",{"name":45,"class":46},"The University of Texas at Arlington","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100592322","immune-targeted-combination-with-chemotherapy-for-acute-leukemia-of-ambiguous-lineage-100592322","NCT06991920","Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage","Immune-targeted Combination With Acute Lymphoblastic Leukemia-like Chemotherapy for Adult of Acute Leukemia of Ambiguous Lineage: A Prospective, Single-arm, Multicenter Clinical Study","Inclusion Criteria:\n\n* A series of acute leukemia of unknown origin diagnosed in accordance with the 5th edition of the WHO or ICC classification standards.\n* Age ≥ 14 years old, regardless of gender.\n* The ECOG performance status score is ≤ 2.\n* Conform to the following organ functional status: total bilirubin \\\u003C 1.5×ULN, AST and ALT ≤ 2.5×ULN; blood Cr \\\u003C 1.5×ULN; myocardial enzymes \\\u003C 2×ULN; serum amylase ≤ 1.5×ULN; echocardiography indicates that the left ventricular ejection fraction (LEF) \\> 50%. (In the case of patients without a previous history of liver or kidney basic disease, if liver and kidney function abnormalities exceed the aforementioned inclusion criteria and the researcher determines that the liver and kidney function abnormalities are caused by acute leukemia itself, they may be included in the group at the researcher's discretion).\n* Understand and sign the informed consent form and agree to abide by the research requirements.\n\nExclusion Criteria:\n\n* Concurrent with other serious and\u002For uncontrollable underlying diseases: accompanied by other malignant diseases requiring treatment, acute or chronic hepatitis, severe pancreatic or kidney diseases; other serious and\u002For life-threatening underlying diseases.\n* Pregnant or lactating women.\n* Positive for anti-HIV test.\n* Mental disorders that may prevent the subject from completing the treatment or giving informed consent.\n* The investigator deems the subject unsuitable for inclusion.","14 Years",{"count":57,"type":23},50,[26],"Acute leukemia of ambiguous lineage (ALAL), which refers to acute leukemia without definite evidence indicating cell differentiation along a specific lineage, mainly encompasses two major categories: acute undifferentiated leukemia (AUL) lacking the expression of lineage-specific antigens and mixed phenotype acute leukemia (MPAL) expressing antigens of two or more lineages. Despite certain advancements in basic research on ALAL, there is currently no unified treatment protocol for this disease. The majority of clinical studies are based on retrospective data, lacking prospective cohort studies. In terms of the overall treatment strategy, given the low chemotherapy remission rate, frequent relapses, and poor prognosis of ALAL, it should be treated as high-risk acute leukemia. Patients achieving complete remission should undergo allogeneic hematopoietic stem cell transplantation as soon as possible if conditions permit. Regarding chemotherapy regimens, the current main regimens utilized in clinical practice include ALL-like regimens, AML-like regimens, and hybrid therapies that incorporate both lymphoid and myeloid lineages. Based on existing research, international consensus guidelines recommend ALL-like regimens as the preferred induction treatment option for ALAL patients. In recent years, novel immunotherapy antibody drugs, such as Blinatumomab (a CD19-targeted drug), have achieved remarkable success in the treatment of B-ALL. However, for CD19+ ALAL, there is a lack of effective data regarding whether the first-line application of immunotherapy can further enhance therapeutic efficacy. Simultaneously, the novel small molecule drug venetoclax has demonstrated favorable therapeutic effects on various hematological malignancies. To enhance the overall therapeutic efficacy of adult ALAL in China, based on the above research, we have formulated a comprehensive treatment plan for adult ALAL, integrating Blinatumomab, ALL-like chemotherapy, venetoclax, and TKI drugs into the systemic treatment regimen, and exploring the safety and efficacy of this regimen in the treatment of adult ALAL.",[29,61],"MPAL","NOT_YET_RECRUITING","2026-02-09",{"date":65,"type":39},"2026-02-11",{"date":67,"type":23},"2026-06-30",{"date":69,"type":23},"2032-04-01",{"name":71,"class":46},"Institute of Hematology & Blood Diseases Hospital, China",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":84,"conditions":85,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100533028","phase-2-a-single-arm-open-label-study-of-olverembatinib-cd3cd19-bispecific-t-cell-engager-and-chidamide-in-patients-with-newly-diagnosed-phall-100533028","NCT06220487","A Single-arm, Open-label Study of Olverembatinib, CD3\u002FCD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL","A Single-arm, Open-label Study of Olverembatinib, CD3\u002FCD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","ABC","Inclusion Criteria:\n\n1. Signed written informed consent;\n2. Newly diagnosed adult B-precursor Ph+ ALL;\n3. Age greater or equal to 18 years;\n4. ECOG Performance Status 0-1;\n5. Ineligible for allo-HSCT.\n6. Renal and hepatic function as defined below:\n\n   AST (GOT), ALT (GPT), and AP \\\u003C2 x upper limit of normal (ULN). Creatinine clearance equal or greater than 50 mL\u002Fmin.\n7. Pancreatic function as defined below:\n\n   Serum amylase less or equal to 1.5 x ULN Serum lipase less or equal to1.5 x ULN\n8. Normal cardiac function;\n9. Negative HIV test, negative HBV DNA and HCV RNA;\n10. Negative pregnancy test in women of childbearing potential.\n\nExclusion Criteria:\n\nHistory of receiving systemic chemotherapy or CAR-T therapy for ALL.\n\nImpaired cardiac function, including any one of the following:\n\n.LVEF \\\u003C45% as determined by MUGA scan or echocardiogram. .Complete left bundle branch block. .Use of a cardiac pacemaker.\n\n* ST depression of \\>1mm in 2 or more leads and\u002For T wave inversions in 2 or more contiguous leads. .Congenital long QT syndrome. .History of or presence of significant ventricular or atrial arrhythmia. .Clinically significant resting bradycardia (\\\u003C50 beats per minute). .QTc \\>450 msec on screening ECG (using the QTcF formula). .Right bundle branch block plus left anterior hemiblock, bifascicular block. .Myocardial infarction within 3 months prior to starting olverembatinib . .Angina pectoris.\n* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of olverembatinib or chidamide (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). .History of or current autoimmune disease. .History of or current relevant CNS pathology. .Presence of CNS leukemia. .History of or current autoimmune disease. .History of other malignancies. .Presence active infection.\n* Nursing women or women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least 3 months thereafter or male patients not willing to ensure effective contraception during participation in the study and at least three months thereafter.\n* Not eigiable for this study, decided by PI",{"count":81,"type":23},67,[83],"PHASE2","ABC study is a phase 2, single-arm, open-label study of Olverembatinib, CD3\u002FCD19 Bispecific T-cell Engager, and Chidamide in patients with newly diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ALL). This study combined third generation TKI (Olverembatinib), histone deacetylase inhibitors (Chidamide) and CD3\u002FCD19 bispecific T-cell engager (Blinatumomab) as first line regimen (ABC regimen) for Ph+ ALL. Investigatorsaim to explore the efficacy and safety of ABC regimen. The primary endpoint is the complete molecular remission （CMR） at 3 months, secondary endpoints are overall survival (OS), event-free survival (EFS), adverse event (AE), IKZF1del, IKZF1plus, IKZF1lpus\u002FCD20 subgroup EFS\u002FOS.",[86,87,88,29,89],"Acute Lymphoblastic Leukemia","Philadelphia Chromosome","Philadelphia-Positive ALL","IKZF1 Gene Mutation",[91,92,93,94,95,86,96],"Olverembatinib","CD3\u002FCD19 Bispecific T-cell Engager","Histone Deacetylase Inhibitor","Chidamide","Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","Ph-positive","2024-01-21",{"date":99,"type":39},"2024-01-24",{"date":101,"type":23},"2024-02-01",{"date":103,"type":23},"2028-01-01",{"name":105,"class":46},"Nanfang Hospital, Southern Medical University",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100529586","treatment-protocol-for-newky-diagnosed-adult-ph-positive-all-100529586","NCT06175702","Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL","Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022)","LALPh2022","Inclusion Criteria:\n\n1. Patients with de novo avute lymphoblastic leukeima (ALL) Philadelphia chromosome-positive (BCR::ABL1) aged ≥18 years.\n2. CML blast crisis will be included. These patients will always receive transplantation, regardless of the molecular response or the genetic risk, following the recommendations of the SEHH CML group (Chronic Myleoid Leukemia Group from the Spanish Society of Hematology).\n3. Performance status 0-2; patients with performance status\\>2 attributable to ALL can be included.\n4. Patients without functional alteration of organs; liver function: total bilirubin, GOT, GPT, GGT and alkaline phosphatase less than 3 times the upper limit of the normal range of the laboratory; renal function: serum creatinine \\\u003C2 mg\u002Fdl or creatinine clearance \\> 30 ml\u002Fmin (except altered renal function attributable to ALL); normal heart function: EF ventricular \\> 50%; absence of severe chronic respiratory disease. In case that the alterations are secondary to the disease, it is at the discretion of the physician to determine if the patient can be included in the study.\n\nExclusion Criteria:\n\n1. Any other subtype of ALL.\n2. Patients with chronic liver disease.\n3. Patients with chronic respiratory failure.\n4. Renal failure not due to ALL.\n5. Lipase and amylase\\>1.5× ULN.\n6. Patients with positive HIV serology.\n7. Serious neurological alterations not due to ALL.\n8. Serious general condition condition (grades 3 or 4 on the WHO scale) not attributable to ALL.\n9. Pregnant or breastfeeding women.\n10. Impaired cardiac function (defined by an ejection fraction less than 50%), any clinically significant active or uncontrolled cardiovascular condition, uncontrolled hypertension, arrhythmias, ischemic cardiovascular or neurological events, deep vein thrombosis, pulmonary thromboembolism, history of acute pancreatitis in the year before diagnosis of ALL or history of chronic pancreatitis and triglycerides \\>450 mg\u002FdL.",{"count":115,"type":23},150,"OBSERVATIONAL","The goal of this prospective, multicenter, open observational study is to assess the efficacy and safety of the treatment for acute lymphoblastic leukemia Ph' positive adult patients with approved combinations of chemotherapy and tyrosine kinase inhibitor (TKI).\n\nEfficay refers to the rate of Complete Molecular Response (BCR::ABL1\u002FABL1 ratio 0.01%) in eah treatment arm. Safety refers to measurement of i) Adverse events (AEs) and serious adverse events (SAEs) according to standard clinical and laboratory tests (hematology and chemistry, physical examination, vital sign measurements, and diagnostic tests), ii) incidence and degree of cytopenias and iii) incidence and degree of infections.\n\nLow-dose chemotherapy will be given together with the TKI imatinib to patients of all ages as induction to remission phase.\n\nConsolidation treatment will continue with low-dose chemotherapy with imatinib if the patient fullfills both criteria: to show a measurable residual disease (MRD) value lower than 0,01% at 3 month of therapy, and not showing IKZF1plus genetics Those patients have any of these 2 conditions will be considered high-risk patients and will recieve consolidation treatment intensification with low-dose chemotherapy plus ponatinib as TKI and allogeneic stem cell transplantation (allo SCT). The remaining patients (standard-risk) will receive maintenance chemotherapy together with imatinib or ponatinib and will not be submitted to alloSCT.",[119,88,29],"Lymphoblastic Leukemia",[86,121,122],"Philadelphia (BCR::ABL1) positive","Adults","2023-12-15",{"date":125,"type":39},"2023-12-19",{"date":127,"type":23},"2023-12-25",{"date":129,"type":23},"2030-12-25",{"name":131,"class":46},"PETHEMA Foundation"]